Analyst Price Target is $8.50
▲ +911.90% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for GlycoMimetics in the last 3 months. The average price target is $8.50, with a high forecast of $13.00 and a low forecast of $4.00. The average price target represents a 911.90% upside from the last price of $0.84.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in GlycoMimetics. This Buy consensus rating has held steady for over two years.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.